<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2056">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04355494</url>
  </required_header>
  <id_info>
    <org_study_id>ECU-COV-401</org_study_id>
    <nct_id>NCT04355494</nct_id>
  </id_info>
  <brief_title>SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19</brief_title>
  <official_title>SOLIRIS® (Eculizumab) for the Treatment of Participants With Coronavirus Disease 2019 (COVID 19) - An Expanded Access Program for Hospital-based Emergency Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      This protocol provides access to eculizumab treatment for participants with severe COVID-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, multicenter, Expanded Access Program (EAP) to allow participants with
      a confirmed diagnosis of SARS-CoV-2 infection, and a clinical presentation consistent with
      COVID-19 severe pneumonia, acute lung injury, or ARDS to be treated with eculizumab.
      Participants admitted to a designated hospital facility who qualify for emergency treatment
      will be administered eculizumab up to 7 times during their treatment course (5 mandatory
      doses and up to 2 optional doses, per Investigator assessment).

      The EAP consists of a Screening Period of up to 7 days, a 4-week Treatment Period, a final
      in-hospital assessment on Day 29 or day of discharge, whichever occurs first, and 3 monthly
      safety follow up visits (to be conducted as a telephone call if the participant has been
      discharged from the hospital or an in-person visit if the participant is still hospitalized).

      For each participant, the total duration of the program is anticipated to be 4.5 months.
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>COVID-19</condition>
  <condition>Pneumonia, Viral</condition>
  <condition>Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>eculizumab</intervention_name>
    <description>Eculizumab at doses of 900-1200 mg will be administered intravenously (up to 7 doses)</description>
    <other_name>Soliris</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females ≥ 18 years of age and ≥ 40 kg at the time of providing informed
             consent.

          2. Confirmed diagnosis of SARS-CoV-2 infection presenting as severe COVID-19 requiring
             hospitalization

          3. Symptomatic, bilateral pulmonary infiltrates confirmed by CT or X-ray at Screening or
             within the 7 days prior to Screening

          4. Severe pneumonia, acute lung injury, or ARDS requiring oxygen supplementation

        Exclusion Criteria:

          1. Confirmed diagnosis of SARS-CoV-2 infection presenting as mild to moderate COVID-19,
             even if the participant is hospitalized

          2. Participant is not expected to survive more than 24 hours

          3. Participant has an unresolved Neisseria meningitidis infection

          4. Hypersensitivity to murine proteins or to one of the excipients of Soliris
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Alexion Pharmaceuticals Inc.</last_name>
    <phone>1-855-752-2356</phone>
    <email>clinicaltrials@alexion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Newton-Wellesley Hospital</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Robert Wood Johnson University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Garches Raymond Poincaré</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Hôpital de Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 17, 2020</study_first_submitted>
  <study_first_submitted_qc>April 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>August 14, 2020</last_update_submitted>
  <last_update_submitted_qc>August 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute lung injury</keyword>
  <keyword>acute respiratory distress syndrome</keyword>
  <keyword>antibodies, monoclonal, humanized</keyword>
  <keyword>complement inhibition</keyword>
  <keyword>COVID-19</keyword>
  <keyword>eculizumab</keyword>
  <keyword>emergency treatment</keyword>
  <keyword>expanded access program</keyword>
  <keyword>hospitalization</keyword>
  <keyword>pneumonia</keyword>
  <keyword>severe acute respiratory syndrome</keyword>
  <keyword>severe acute respiratory syndrome coronavirus 2</keyword>
  <keyword>severe pneumonia</keyword>
  <keyword>Soliris</keyword>
  <keyword>viral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Viral</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

